专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20150209391A1 Cancer Treatment Composition 审中-公开
标题翻译：癌症治疗组成
公开(公告)号：US20150209391A1
公开(公告)日：2015-07-30
申请号：US14605126
申请日：2015-01-26
申请人： Samir Witta
发明人： Samir Witta
IPC分类号： A61K35/644 , A61K45/06 , A61K31/352 , A61K31/05 , A61K31/12
CPC分类号： A61K35/644 , A61K31/05 , A61K31/12 , A61K31/352 , A61K36/074 , A61K36/185 , A61K36/815 , A61K45/06 , A61K2300/00
摘要： A cancer treatment composition that includes natural substances. The cancer treatment composition functions by inhibiting growth and formation of cancer cells by inhibiting specific pathways. Specifically, the composition provides a combination of Wnt signaling pathway inhibitors and histone deacetylase inhibitors. Preferably, the composition includes therapeutically effective amounts of dimethoxycurcumin and/or quercitin for inhibiting the Wnt signaling pathway, and honokiol and royal jelly for inhibiting histone deacetylase. The composition may further include one or more antitumorigenic compounds such as graviola guanabana, lyceum barbarum, gogi, red reishi, and salvestrol, among others. Thus, the present invention provides a cancer treatment composition having natural substances and compounds.
摘要翻译：包含天然物质的癌症治疗组合物。癌症治疗组合物通过抑制特异性途径抑制癌细胞的生长和形成而起作用。具体地，该组合物提供Wnt信号通路抑制剂和组蛋白脱乙酰酶抑制剂的组合。优选地，组合物包含用于抑制Wnt信号通路的治疗有效量的二甲氧基姜黄素和/或槲皮素，以及用于抑制组蛋白脱乙酰酶的和厚朴酚和蜂王浆。该组合物可以进一步包括一种或多种抗致癌性化合物，例如红景天，枸杞子，沐浴露，红ishi ishi和沙司韦等。因此，本发明提供了具有天然物质和化合物的癌症治疗组合物。

2. 发明申请

US20070270505A1 Gefitinib Sensitivity-Related Gene Expression and Products and Methods Related Thereto 有权
标题翻译：吉非替尼敏感性相关基因表达及相关产品及方法
公开(公告)号：US20070270505A1
公开(公告)日：2007-11-22
申请号：US10587052
申请日：2005-01-24
申请人： Paul Bunn Jr. , Christopher Coldren , Wilbur Franklin , Mark Geraci , Barbara Helfrich , Fred Hirsch , Razvan Lapadat , Michio Sugita , Samir Witta
发明人： Paul Bunn Jr. , Christopher Coldren , Wilbur Franklin , Mark Geraci , Barbara Helfrich , Fred Hirsch , Razvan Lapadat , Michio Sugita , Samir Witta
IPC分类号： A61K31/00 , A61P35/00 , C12Q1/02 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136
摘要： Disclosed is the identification, provision and use of a panel of biomarkers that predict sensitivity or resistance to gefitinib and other EGFR inhibitors, and products and processes related thereto. Specifically, a method is described for selecting a cancer patient who is predicted to benefit from therapeutic administration of an EGFR inhibitor, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitor. Also described is a method to identify molecules that interact with the EGFR pathway to allow or enhance responsiveness to EGFR inhibitors, as well as a plurality of polynucleotides or antibodies for the detection of the expression of genes that are indicative of sensitivity or resistance to EGFR inhibitors, an agonist thereof, or a drug having substantially similar biological activity as EGFR inhibitors. A method to identify a compound with the potential to enhance the efficacy of EGFR inhibitors is also described.
摘要翻译：公开了鉴定，提供和使用一组生物标志物，其预测对吉非替尼和其他EGFR抑制剂的敏感性或抗性，以及与之相关的产品和过程。具体地说，描述了一种用于选择预期从治疗性施用EGFR抑制剂，其激动剂或具有与EGFR抑制剂具有实质上相似的生物学活性的药物中受益的癌症患者的方法。还描述了鉴定与EGFR途径相互作用以允许或增强对EGFR抑制剂的反应性的分子的方法，以及用于检测指示EGFR抑制剂的敏感性或抗性的基因表达的多种多核苷酸或抗体，其激动剂，或具有与EGFR抑制剂基本相似的生物学活性的药物。还描述了鉴定具有增强EGFR抑制剂功效潜力的化合物的方法。

3. 发明申请

US20070197568A1 Methods of using SAHA and Erlotinib for treating cancer 审中-公开
标题翻译：使用SAHA和厄洛替尼治疗癌症的方法
公开(公告)号：US20070197568A1
公开(公告)日：2007-08-23
申请号：US11592443
申请日：2006-11-03
申请人： Paul Bunn , Samir Witta , Victoria Richon , Stanley Frankel , Paul Deutsch , Sophia Randolph
发明人： Paul Bunn , Samir Witta , Victoria Richon , Stanley Frankel , Paul Deutsch , Sophia Randolph
IPC分类号： A61K31/517 , A61K31/19
CPC分类号： A61K31/167 , A61K31/19 , A61K31/517 , A61K2300/00
摘要： The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
摘要翻译：本发明涉及通过对有需要的受试者施用第一量的组蛋白脱乙酰酶（HDAC）抑制剂如辛二酰苯胺异羟肟酸（SAHA）或其药学上可接受的盐，治疗有需要的受试者的癌症的方法或其水合物，以及第二量的一种或多种抗癌剂，包括厄洛替尼。 HDAC抑制剂和抗癌剂可以施用以包含治疗有效量。在各个方面，HDAC抑制剂和抗癌剂的作用可以是相加的或协同的。

4. 发明申请

US20080221138A1 Method of using SAHA and Erlotinib for treating cancer 审中-公开
标题翻译：使用SAHA和厄洛替尼治疗癌症的方法
公开(公告)号：US20080221138A1
公开(公告)日：2008-09-11
申请号：US12150999
申请日：2008-05-02
申请人： Paul Bunn , Samir Witta , Victoria M. Richon , Stanley R. Frankel , Paul J. Deutsch , Sophia Randolph
发明人： Paul Bunn , Samir Witta , Victoria M. Richon , Stanley R. Frankel , Paul J. Deutsch , Sophia Randolph
IPC分类号： A61K31/517 , A61P35/00
CPC分类号： A61K31/167 , A61K31/19 , A61K31/517 , A61K2300/00
摘要： The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.
摘要翻译：本发明涉及通过对有需要的受试者施用第一量的组蛋白脱乙酰酶（HDAC）抑制剂如辛二酰苯胺异羟肟酸（SAHA）或其药学上可接受的盐，治疗有需要的受试者的癌症的方法或其水合物，以及第二量的一种或多种抗癌剂，包括厄洛替尼。 HDAC抑制剂和抗癌剂可以施用以包含治疗有效量。在各个方面，HDAC抑制剂和抗癌剂的作用可以是相加的或协同的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式